Breast Cancer Research and Treatment

, Volume 112, Issue 1, pp 175–187

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

  • Masahide Kondo
  • Shu Ling Hoshi
  • Hiroshi Ishiguro
  • Hiroshi Yoshibayashi
  • Masakazu Toi
Epidemiology

DOI: 10.1007/s10549-007-9842-y

Cite this article as:
Kondo, M., Hoshi, S.L., Ishiguro, H. et al. Breast Cancer Res Treat (2008) 112: 175. doi:10.1007/s10549-007-9842-y
  • 172 Views

Abstract

The 21-gene reverse transcriptase-polymerase chain reaction assay with a patented algorithm is validated as a good predictor of prognosis and potential benefit from adjuvant chemotherapy for lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer, while its high cost raises concern about how to finance it. Cost-effectiveness analysis comparing prevalent National Comprehensive Cancer Network (NCCN) guideline/St Gallen recommendation-guided treatment with the assay-guided treatment is carried out with budget impact estimation in the context of Japan’s health care system. Incremental cost-effectiveness ratios are estimated as 2,997,495 ¥/QALY (26,065 US$/QALY) in the comparison between NCCN guided-treatment vs. the assay-guided treatment, and as 1,239,055 ¥/QALY (10,774 US$/QALY) in the comparison between St Gallen guided-treatment vs. the assay-guided treatment. Budget impact is estimated as ¥2,638 million (US$23 million) to ¥3,225 million (US$28 million) per year. The routine use of the assay is indicated as cost-effective. And the budget impact could be judged as within fundable level.

Keywords

Breast cancerBudget impactCost-effectivenessGene diagnosis21-gene signatureTailor-made medicine

Copyright information

© Springer Science+Business Media, LLC. 2007

Authors and Affiliations

  • Masahide Kondo
    • 1
    • 2
  • Shu Ling Hoshi
    • 3
  • Hiroshi Ishiguro
    • 4
  • Hiroshi Yoshibayashi
    • 5
  • Masakazu Toi
    • 5
  1. 1.Department of Health Care Policy and Management, Graduate School of Comprehensive Human SciencesUniversity of TsukubaTsukubaJapan
  2. 2.Clinical Research DivisionTokyo Metropolitan Cancer and Infectious Disease Center, Komagome HospitalTokyoJapan
  3. 3.Doctoral Program in Human-Care Sciences, Graduate School of Comprehensive Human SciencesUniversity of TsukubaTsukubaJapan
  4. 4.Department of Translational Clinical Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan
  5. 5.Department of Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan